Atezolizumab (anti–PD-L1) Combo in Non-Sq NSCLC: PFS Benefit Falls Short of Significance
- Trial ID
- NCT04194203 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer
- Published in
- New in Oncology - May 29, 2025
The IMpower151 trial (NCT04194203) combined atezolizumab plus bevacizumab and chemotherapy for first-line metastatic non-squamous NSCLC for 305 patients in China. Patients in the ABCPem/Pac arm (atezolizumab, bevacizumab, carboplatin and pemetrexed/paclitaxel) achieved a median INV-PFS of 9.5 months versus 7.1 months for the BCPem/Pac arm, with similar OS (20.7 vs. 18.7 months). Adverse events that led to discontinuation of any treatment were observed in 23% and 15% of patients receiving ABCPem/Pac and BCPem/Pac, respectively.
Take home
The findings indicate the atezolizumab plus bevacizumab and chemotherapy shows ~2 month improvement in mPFS compared to bevacizumab and chemotherapy with similar tolerability. Unfortunately the overall survival benefits did not look significant, so the combination is unlikely to become standard of care.
Source: Read the original publication
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC